Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Published:2019-07 Issue:7 Volume:20 Page:924-937
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

West Howard,McCleod Michael,Hussein Maen,Morabito Alessandro,Rittmeyer Achim,Conter Henry J,Kopp Hans-Georg,Daniel Davey,McCune Steven,Mekhail Tarek,Zer Alona,Reinmuth Niels,Sadiq Ahad,Sandler Alan,Lin Wei,Ochi Lohmann Tania,Archer Venice,Wang Lijia,Kowanetz Marcin,Cappuzzo Federico

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

2. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1;Chen;Clin Cancer Res,2012

3. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014

4. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer;Powles;Nature,2014

5. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial;Fehrenbacher;Lancet,2016

Cited by 1239 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sleep disturbance as a poor prognostic predictor in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A prospective study;Journal of Psychosomatic Research;2024-11

2. Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer;Cancers;2024-09-11

3. Opportunistic Features of Non-Clostridium botulinum Strains Containing bont Gene Cluster;Pathogens;2024-09-10

4. MYC plus class IIa HDAC inhibition potentiates mitochondrial dysfunction in non-small cell lung cancer;2024-09-08

5. Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis;ESMO Open;2024-09